Vimarsana
Biggest News Aggregation in the World

Flare Index News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Flare Index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Flare Index Today - Breaking & Trending Today

AbbVie - Phase 2 Study of Upadacitinib Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus - Vimarsana News

AbbVie - Phase 2 Study of Upadacitinib Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

Published: June 1, 2023

NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active... | June 1, 2023

Source: marketscreener.com
Related Topics:
United StatesRoopal ThakkarKristin PawliwJoan MerrillExchange CommissionLupus Erythematosus National AssessmentArthritis Clinical Immunology Research ProgramEuropean CongressOklahoma Medical Research FoundationFlare IndexLupus Low Disease Activity StateMedical Research FoundationClinical Immunology ResearchAllergan AestheticsPrivate Securities Litigation Reform ActRisk FactorsQuarterly ReportsNews PublishingAbbvie Inc Stock ExchangePress ReleaseEverely Abbv Us00287y1091
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus - Vimarsana News

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

Published: May 31, 2023

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary...

Source: prnewswire.com
Related Topics:
United StatesJoan MerrillRoopal ThakkarUpadacitinib MonotherapyArthritis Clinical Immunology Research ProgramCenters For DiseaseEuropean CongressLupus Erythematosus National AssessmentExchange CommissionOklahoma Medical Research FoundationAbbvie Deutschland Gmbh CoBritish Isles Lupus Assessment GroupResponder IndexLupus Low Disease Activity StateFlare IndexClinical Immunology ResearchAllergan AestheticsPrivate Securities Litigation Reform ActQuarterly ReportsFinal LockKey ResultsIntended IndicationSystemic Lupus ErythematosusAdult Systemic Lupus ErythematosusDisease Activity
Upadacitinib Demonstrates Significant Improvements in Disease Activity, Flare in SLE - Vimarsana News

Upadacitinib Demonstrates Significant Improvements in Disease Activity, Flare in SLE

Published: May 31, 2023

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

Source: hcplive.com
Related Topics:
United StatesRoopal ThakkarJoan MerrillEuropean CongressArthritis Clinical Immunology Research ProgramLupus Foundation Of America Joan MerrillBritish Isles Lupus Assessment GroupOklahoma Medical Research FoundationLupus FoundationClinical Immunology ResearchFlare IndexLupus Low Disease Activity State